Consistent with our data, previous research has shown that SMAD4 reduction is associated with phenotypes such as tumor progression and metastasis in some cancers including lung cancer (Fukuchi et al., 2002; He et al., 2011; Tan et al., 2021), therefore is supportive with our findings of PDH inhibition leading to a more aggressive phenotype. Here, PDP1 is linked to neoplasm.